. Akorn (WKN: 888920)AKRX
Seite 1 von 3 Neuester Beitrag: 31.05.20 13:13 | ||||
| Eröffnet am: | 07.12.15 21:57 | von: Tamakoschy | Anzahl Beiträge: | 58 |
| Neuester Beitrag: | 31.05.20 13:13 | von: Vassago | Leser gesamt: | 22.593 |
| Forum: | Börse | Leser heute: | 12 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 > | ||||
Logo Akorn, Inc.
Manufactures and distributes therapeutic, diagnostic and surgical pharmaceuticals
Akorn, Inc. manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.
It also markets and distributes vaccines purchased from outside sources.
The company customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies.
It operates through three segments: Ophthalmic, Hospital Drugs & Injectables and Contract Services.
The Ophthalmic segment market a full line of diagnostic and therapeutic ophthalmic pharmaceutical products.
The diagnostic products, primarily used in the office setting include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others.
The therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications.
The non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers.
The Hospital Drugs & Injectables segment markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other selected pharmaceutical products.
These products are predominately sold to hospitals through the wholesale distribution channel.
The Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications.
The company was founded in 1971 and is headquartered in Lake Forest, IL.
Mitarbeiteranzahl : 1 665 Personen.
http://de.4-traders.com/AKORN-INC-42504/fundamentals/
http://investors.akorn.com/phoenix.zhtml?c=78132&p=irol-irhome
Akorn meldet Zahlen für Q1/19
- Umsätze 166 Mio. $
- Verlust 82 Mio. $
- Cash 185 Mio. $
- Equity 366 Mio. $
- weiter Finger weg!
Akorn's full year 2019 guidance:
- Net revenue for the year expected to be in the range of $690 to $710 million
- Net Loss expected in the range of ($166) to ($151) million
- Adjusted EBITDA expected in the range of $71 to $86 million
- Approximately $40 million in capital expenditures
- Approximately $40 million for data integrity investigation and FDA compliance related expenditures
http://investors.akorn.com/news-releases/...ter-2019-results-and-full
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Stillhaltevereinbarung mit den Kreditgebern läuft bis zum 15.November 2019
https://www.fiercepharma.com/manufacturing/...ment-not-reached-within
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Akorn meldet Zahlen für Q2/19
- Umsatz 178 Mio. $
- Verlust 112 Mio. $
- Cash 178 Mio. $
- Equity 261 Mio. $
Ich seh hier schwarz, Akorn macht jedes Quartal satte Verluste, in vorraussichtlich 2-3 Quartalen ist die Eigenkapitalquote negativ, falls nicht vorher etwas passiert (siehe #36)
http://investors.akorn.com/news-releases/...cond-quarter-2019-results
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Vergleich über 74 Mio. $ mit Investoren
- neues 52 Wochen-Tief!
https://www.fiercepharma.com/pharma/...stors-over-data-integrity-woes
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Warnung vor möglichen Bankrott
https://seekingalpha.com/article/...rns-of-possible-bankruptcy-filing
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Stillhaltevereinbarung bis zum 7. Ferbuar 2020
Was meiner Meinung nach nicht bedeutet das Akorn nicht vorher Pleite gehen könnte, es ist eher als Deadline zu sehen um alle Alternativen zu prüfen.
https://seekingalpha.com/news/3527164-akorn-adds-to-selloff-down-21
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Optionen
| Boardmail an "wallander" |
Wertpapier: Akorn |
akrx.png (verkleinert auf 72%)
Chapter 11 jederzeit möglich
https://www.fiercepharma.com/manufacturing/...rs-negotiate-its-future
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Zahlen für Q4/19
- Umsatz 162 Mio. $ (VJQ 153)
- Verlust 81 Mio. $ (VJQ 215)
- Cash 145 Mio. $
- MK 141 Mio. $
"Reached an agreement with our lenders to execute a sale of Akorn’s business, potentially using Chapter 11 protection, as previously disclosed on the Company’s Form 8-K filed on February 12, 2020."
http://investors.akorn.com/news-releases/...nd-full-year-2019-results
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Pleite in den nächsten Tagen/Wochen?
"Akorn, Inc. a leading specialty pharmaceutical company, today announced that it no longer has any bids in the Sale Process that are sufficient to pay all obligations under its term loan agreement."
http://investors.akorn.com/news-releases/...vides-update-sale-process
https://seekingalpha.com/news/...lts-on-loan-shares-down-20-premarket
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Zahlen für Q1/20
- Umsatz 205 Mio. $
- Verlust 257 Mio. $
- inkl. Goodwill-Abschreibung in Höhe von 268 Mio. $
- inkl. Goodwill-Abschreibung in Höhe von 268 Mio. $
- Cash 72 Mio. $
- EK -19 Mio. $
"Discussions with lenders regarding the sale process and Chapter 11 filing are on-going"
http://investors.akorn.com/news-releases/...irst-quarter-2020-results
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |
Optionen
| Boardmail an "Vassago" |
Wertpapier: Akorn |